0001144204-12-050644.txt : 20120911 0001144204-12-050644.hdr.sgml : 20120911 20120911160159 ACCESSION NUMBER: 0001144204-12-050644 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120910 FILED AS OF DATE: 20120911 DATE AS OF CHANGE: 20120911 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TG THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 787 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: (212) 554-4484 MAIL ADDRESS: STREET 1: 787 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030310 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WEISS MICHAEL S CENTRAL INDEX KEY: 0001038977 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32639 FILM NUMBER: 121085712 MAIL ADDRESS: STREET 1: 750 LEXINGTON AVE CITY: NEW YORK STATE: NY ZIP: 10022 4 1 v323523_4.xml OWNERSHIP DOCUMENT X0306 4 2012-09-10 0 0001001316 TG THERAPEUTICS, INC. TGTX 0001038977 WEISS MICHAEL S 787 SEVENTH AVENUE, 48TH FLOOR NEW YORK NY 10019 1 1 1 0 See Remarks COMMON STOCK 2012-09-10 4 P 0 50000 2.25 A 7242728 D COMMON STOCK 2012-09-11 4 P 0 100000 2.25 A 7342728 D Includes a grant of restricted shares that will vest according to the following schedule: 50% in equal installments on the 3rd, 4th, and 5th anniversary of the date of grant; 25% on the first date that the issuer achieves a pre-established market capitalization target; and 25% on the first date that the issuer achieves another pre-established market capitalization target. Also includes 1,000,000 shares of Common Stock, which vest as follows: 125,000 on each of November 15, 2012, November 15, 2013, November 15, 2014, and November 15, 2015; 250,000 upon the occurrence of the registrant achieving a particular market capitalization target; and 250,000 upon the occurrence of the registrant achieving a second particular market capitalization target. In addition, Mr. Weiss purchased shares in the Offering conducted by the Company which closed on December 30, 2011. As a result of that purchase he owns 133,334 shares of Common Stock, and 33,334 warrants to purchase Common Stock at $2.25, exercisable for five years. Finally, also included in Mr. Weiss' beneficial ownership are 4,524,560 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest. Executive Chairman, Interim CEO and President /s/ Michael Weiss 2012-09-11